BOBULSKY SUSAN sold $102K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 5,000 shares of Adaptive Biotechnologies Corp (ADPT) at $20.50 ($0.10M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This is a pre-arranged 10b5-1 open-market sale by a senior officer; it is typically not a strong standalone catalyst for price action.
Market read
Confirms a scheduled insider sale (5,000 shares at $20.50) with limited incremental information for trading decisions.
What to watch
The article provides no context on total insider holdings beyond the post-transaction figure, and does not indicate any change in company fundamentals—so the signal-to-noise is low.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
Adaptive Biotechnologies insider (Chief Commercial Officer) sold 5,000 shares at $20.50 on 2026-06-25 under a 10b5-1 plan.
Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.
The filing is a Form 4 insider transaction explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.
Market effects
No direct sector read-through; this is company-specific insider liquidity rather than a biotech/clinical catalyst.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can still coincide with internal confidence if the plan is simply executed on schedule; traders may overreact to the headline framing of “selling.”
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider transaction disclosure.
- insiderBOBULSKY SUSAN
Chief Commercial Officer (MRD) who sold shares under a 10b5-1 plan.